HRT and Menopause in the UK: The Complete Evidence-Based Guide

Menopause: What's Actually Happening

Menopause, the permanent cessation of menstruation, occurs at a median age of 51 in the UK, though the perimenopause (the transition phase) can begin 4–8 years earlier. During perimenopause, oestrogen and progesterone levels fluctuate unpredictably before declining permanently. Approximately 75% of women experience vasomotor symptoms (hot flushes, night sweats), and 25% describe them as severe. But menopause symptoms extend far beyond hot flushes: brain fog and difficulty concentrating, mood changes (anxiety, irritability, low mood), sleep disruption, joint pain and stiffness, vaginal dryness and urinary symptoms, reduced libido, and changes in body composition. These symptoms can persist for an average of 7–10 years and significantly impact quality of life, relationships, and career. Yet women in the UK wait an average of 2 years from symptom onset before seeking medical help.

The Evidence on HRT: Safety and Efficacy

HRT is the most effective treatment for vasomotor symptoms (hot flushes, night sweats), reducing their frequency by approximately 75–90%. The landmark Women's Health Initiative (WHI) study in 2002 initially caused a dramatic decline in HRT prescribing due to concerns about breast cancer and cardiovascular risk. However, re-analysis of the WHI data and subsequent large-scale studies have substantially revised the risk picture. For women starting HRT within 10 years of menopause (or under age 60): cardiovascular risk is actually reduced, breast cancer risk with combined HRT is approximately 4 additional cases per 1,000 women over 5 years (comparable to the risk from drinking 2 glasses of wine daily or being obese), oestrogen-only HRT (for women without a uterus) shows no significant increase in breast cancer risk, bone fracture risk is significantly reduced, and there may be a protective effect against dementia. The current position of NICE, the British Menopause Society, and the International Menopause Society is that the benefits of HRT outweigh the risks for the majority of symptomatic women under 60.

Types of HRT Available in the UK

HRT comes in several forms: oestrogen can be delivered as tablets (oral oestradiol, brands include Elleste, Progynova), patches (Evorel, Estradot), gels (Oestrogel, Sandrena), or spray (Lenzetto). Transdermal oestrogen (patches, gels, sprays) is preferred because it bypasses the liver and carries no additional blood clot risk, unlike oral oestrogen. If you have a uterus, you also need progesterone to protect the uterine lining: options include the Mirena IUS (which also provides contraception), micronised progesterone (Utrogestan, the body-identical option with the most favourable safety profile), or synthetic progestogens (norethisterone, medroxyprogesterone). Testosterone supplementation (currently prescribed off-label in the UK using products like Androfeme or compounded preparations) can address low libido, fatigue, and cognitive symptoms that do not respond to oestrogen alone.

Getting HRT from Your GP: Overcoming Reluctance

Despite clear NICE guidance (NG23), many GPs remain hesitant to prescribe HRT, often citing outdated concerns about breast cancer risk. If your GP is reluctant: cite NICE guideline NG23, which states that HRT should be offered as first-line treatment for vasomotor symptoms; request a referral to an NHS menopause clinic if available (waiting times vary from 4 weeks to 12+ months); or consider a private menopause consultation (£150–400) with a British Menopause Society-accredited specialist. The BMS website (thebms.org.uk) maintains a register of accredited menopause specialists. Some women access HRT through online services such as Health and Her, Stella, or The Menopause Clinic, these provide remote consultations with menopause specialists and can issue private prescriptions.

Perimenopause: When Blood Tests Don't Help

A common frustration: women with perimenopause symptoms are told by their GP that blood tests show 'normal hormones' and therefore they cannot be perimenopausal. This is clinically incorrect. During perimenopause, hormone levels fluctuate wildly, a single blood test captures one moment in a constantly changing picture. NICE guideline NG23 explicitly states that hormone blood tests should NOT be used to diagnose perimenopause in women over 45 with typical symptoms. Diagnosis should be made on clinical grounds, based on symptoms and menstrual history. If your GP insists on testing hormones to 'prove' perimenopause, this reflects outdated practice. For women under 45 with menopausal symptoms, FSH testing on two occasions 4–6 weeks apart is appropriate to investigate premature ovarian insufficiency.

Beyond HRT: Comprehensive Menopause Management

While HRT addresses the hormonal component of menopause, comprehensive management may also include: cognitive behavioural therapy (CBT), NICE-recommended for mood symptoms and vasomotor symptoms, with evidence showing 50–70% reduction in hot flush severity; regular exercise, both aerobic and resistance training improve mood, sleep, bone density, and cardiovascular health; vaginal oestrogen (Vagifem, Ovestin), a local treatment for vaginal dryness and urinary symptoms that can be used alongside systemic HRT and continued indefinitely; dietary adjustments, calcium (1,000mg daily from dietary sources), vitamin D supplementation (1,000–2,000 IU daily), and reducing alcohol and caffeine intake, which can worsen vasomotor symptoms. Treatments without strong evidence include: most herbal supplements (black cohosh, red clover, evening primrose oil, limited efficacy data and potential interactions with HRT), phytoestrogens (isoflavones from soy, modest evidence for mild symptoms only), and bioidentical hormone compounding (unregulated, inconsistent dosing, not recommended by the BMS or NICE).